Retinoic acid receptor Inhibitors
5 drugsAbout Retinoic acid receptor
The Retinoic Acid Receptor (RAR) is a nuclear receptor protein that regulates gene expression in response to retinoic acid. As a ligand-activated transcription factor, RAR influences a wide array of cellular processes.
While there is currently no genetic evidence directly linking RAR to specific diseases, the clinical success of several drugs targeting this receptor underscores its importance. Further research could unlock new therapeutic opportunities in areas such as dermatology.
RAR is targeted by 5 FDA-approved drugs, including ADAPALENE, ADAPALENE AND BENZOYL PEROXIDE, EPIDUO FORTE, EPIDUO, and CABTREO. All approved drugs are small molecules and are approved for "other" therapeutic areas.
Top Retinoic acid receptor Drugs
Five companies have approved drugs targeting RAR, including WAYLIS THERAP and GALDERMA LABS.
The presence of multiple players indicates moderate competition, requiring strong differentiation.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| ADAPALENE AND BENZOYL PEROXIDE | ENCUBE | 2015 | 1 |
| EPIDUO FORTE | GALDERMA LABS | 2015 | 1 |
Retinoic acid receptor Drug Modality Landscape
Modalities
Routes of Administration
Retinoic acid receptor is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies could provide a competitive advantage.
Retinoic acid receptor Clinical Trials 111 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Retinoic acid receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 13 | 1 | 1 | 93% |
| Phase 2 | 15 | 8 | 3 | 4 | 73% |
| Phase 3 | 29 | 25 | 2 | 2 | 93% |
| Phase 4 | 52 | 39 | 1 | 12 | 98% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Retinoic acid receptor Drug Approval Timeline (2010 - 2023)
The first drug was approved in 2008, and the most recent was approved in 2023.
The continued approvals suggest ongoing interest, but market saturation may be approaching.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 66 (23 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Retinoic acid receptor. A trial counts if an approved drug acting on Retinoic acid receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.